Gin_slovin_nihms600845

Enhancing the Immunogenicity of Cancer Vaccines with QS21

August 20, 2011

Off

Share This

Adjuvance co-founder David Gin describes the clinical use of QS-21 as an adjuvant in developing and enhancing cancer vaccines.

Related Posts

fochesato_AS01_HuVac

Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine

Hz_su_NEJM_nejmoa150118

NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine

leroux-roels_1-s2.0-S0264410X14014698-main

Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

tejada_bioorg

Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol

Copyright 2009-2016. All rights reserved.